tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'EMA'

Nuvilex’s Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target

Written by Ι Stock Market Media Group Staff — October 14, 2014

New York, NY – Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an application asking the agency to grant orphan drug status to its Cell-in-a-Box/ifosfamide combination for the rare disease.

The FDA’s orphan drug program designates a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 ...

Read More →
0

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition

Written by ι Stock Market Media Group — April 22, 2014

When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for “Orphan Drug” status.  This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide.

Treatments for pancreatic cancer engender an Orphan Drug designation in most ...

Read More →
0
ContactUs.com